Quick Answer
There is no single yes or no answer to "are peptides legal," because "peptides" describes a chemical shape, not a legal status. A drug store GLP-1 injection, a compounding pharmacy's prescription, and a vial labeled "research use only" can all contain a peptide, and each one sits in a completely different part of federal drug law. The table below is the short version. The rest of this guide walks through each category in plain language.
| Category | Current status (October 2026) |
|---|---|
| FDA-approved peptide drugs | Legally available by prescription, went through full FDA clinical review. Examples: semaglutide, tirzepatide. |
| Compounded peptides under Section 503A | Allowed by prescription for six peptides (BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon) under a draft HHS policy announced October 28, 2026, with strict conditions. None are on the 503A Bulks List yet, and others such as CJC-1295 and ipamorelin are not covered. |
| Research chemicals ("not for human consumption") | How most commonly discussed research peptides are currently sold. Not reviewed by the FDA for safety or efficacy. |
| Import, customs, and state rules | Varies and can change. General information only, not something to rely on for a specific decision. |
Why "Peptides" Isn't One Legal Category
It helps to stop thinking of "peptide" as a legal term at all. It's a chemistry term, describing a short chain of amino acids. Insulin is a peptide. Semaglutide is a peptide. BPC-157 is a peptide. Those three have wildly different legal statuses, because what determines legality isn't the molecule itself, it's how that specific substance has moved, or hasn't moved, through the FDA's regulatory pathways.
Broadly, a peptide discussed on a site like this one falls into one of four buckets: an FDA-approved drug available by prescription, a substance a compounding pharmacy could legally prepare under Section 503A, a research chemical sold without a drug claim, or a substance whose status is additionally shaped by import and state-level rules. Each is covered in its own section below.
1. FDA-Approved Peptide Drugs
This is the only category where the legal picture is genuinely simple. An FDA-approved peptide drug has gone through the FDA's full clinical trial process, meaning studies on safety and effectiveness were reviewed and the agency signed off on a specific formulation, dose, and indication. These are available legally by prescription through a licensed pharmacy.
The clearest current examples are semaglutide and tirzepatide, both FDA-approved GLP-1 receptor agonist drugs used for weight management and type 2 diabetes, sold under brand names most people recognize. See our full semaglutide vs. tirzepatide comparison for how the two approved drugs differ.
The sermorelin history worth knowing
Sermorelin has an interesting regulatory past that gets conflated with its present. It was once FDA-approved under the brand name Geref for pediatric growth hormone deficiency. That approved product was later discontinued commercially, and importantly, that discontinuation was a business decision, not a safety withdrawal. That history does not carry over to the sermorelin sold today as a research chemical. A product being sold under that name now does not have the same regulatory status as the discontinued, once-approved Geref formulation. See FDA-Approved Peptides vs. Research Peptides for more on how these two categories get confused.
2. Compounded Peptides Under Section 503A
Section 503A of the Federal Food, Drug, and Cosmetic Act lets a licensed pharmacy legally compound a substance for an individual patient's prescription, but only under specific conditions. The substance has to meet at least one of three requirements: it's on the FDA's Section 503A Bulk Drug Substances List, it has its own U.S. Pharmacopoeia or National Formulary (USP/NF) monograph, or it's a component of an already FDA-approved drug.
As of October 30, 2026, none of the commonly discussed research peptides, including BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, CJC-1295, Ipamorelin, Selank, and DSIP, are on that Bulk Drug Substances List. Until late October 2026, that meant a compounding pharmacy could not legally prepare any of them under Section 503A. That changed for six of them with the draft HHS policy described below. CJC-1295, Ipamorelin, Selank and DSIP are still not covered.
What did change in 2026: on July 23 to 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding six of seven reviewed peptides, BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, to the 503A Bulks List. DSIP, reviewed under the name Emideltide, was the one substance the committee did not recommend.
What changed in October 2026: on October 28, 2026, the U.S. Department of Health and Human Services announced a draft enforcement discretion policy for 503A compounding of those same six peptides, published in the Federal Register on October 30, 2026 (FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496) as a nonbinding draft, with public comments open until about November 13, 2026. Licensed 503A pharmacies may now compound BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon for individual patients with a valid prescription, as long as they meet the policy's conditions (Frier Levitt summary).
The conditions are strict: one peptide per product (no blends), an ingredient from an FDA-registered manufacturer following current good manufacturing practice with the facility named on its certificate of analysis, full testing for identity, purity, potency, impurities and endotoxins, specific routes of use for each peptide, a "This is a compounded drug product. Not for resale." label, and adverse event reporting through FDA's MedWatch program. It does not cover 503B outsourcing facilities or research chemical sellers.
It's still easy to overstate what this means. The draft policy is not FDA approval and does not add these peptides to the 503A Bulks List. It is non-binding, does not override state pharmacy rules, and HHS can revise or withdraw it. Permanent inclusion on the list still requires FDA to complete a formal notice-and-comment rulemaking process, expected to take roughly 12 to 24 months, or Congress to amend the underlying statute. For a step-by-step look at the legal routes, see How to Get Peptides Legally. For the full story on that vote, including how the committee split and what happens next, see What Changed With BPC-157, TB-500 and MOTS-c in 2026. For the current status of every individual compound, updated as things change, see the FDA Peptide Status Tracker. For a deeper explanation of what "compounded" actually means and how it differs from a manufactured drug, see What Is a Compounded Peptide?.
3. Research Chemicals Sold "Not for Human Consumption"
This is how most of the peptides discussed on BioStackIQ, including BPC-157, TB-500, MOTS-c, CJC-1295, Ipamorelin, Selank, Semax, Epithalon, KPV, and DSIP, are currently sold: as research chemicals labeled "research use only" or "not for human consumption."
In plain terms, that labeling generally means the seller isn't making a drug claim about the product, and the product hasn't gone through FDA review for human safety or efficacy. It's a way of selling a compound outside the drug approval framework entirely, rather than a claim that the product has been evaluated and found safe.
What that labeling does not automatically mean is that possessing the substance itself is illegal. That said, this is genuinely where general information has to stop and individual legal judgment has to start. How a product is marketed, what claims are made about it, and how it's actually used can raise separate legal questions from the labeling alone, and those questions depend on specifics this article can't evaluate for you. We're not able to give a definitive answer about what any individual reader may or may not legally do, and this section should be read as general information only, not legal advice. If this matters for your situation, get your own legal counsel. For more on what the "research use only" label does and doesn't mean, see What Does "Research Use Only" Actually Mean?.
4. Import, Customs, and State-Level Variation
There's one more layer worth flagging briefly: how a peptide shipment is treated at customs, and how individual states approach these substances, can both vary and can change over time. This is a genuinely complex, moving area, and it's not something a single article can map out completely or keep current on its own. If import or state-specific rules matter for your situation, treat this section as a pointer to go look into it further, not as a complete answer.
How to Think About This as a BioStackIQ User
Put together, the picture looks like this: a small number of peptides, like semaglutide and tirzepatide, are FDA-approved prescription drugs. Six commonly discussed peptides, BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon, can now be compounded by licensed 503A pharmacies with a prescription under a draft HHS policy from October 2026, while others such as CJC-1295, Ipamorelin, Selank and DSIP still cannot. Most of what's actually sold and discussed today falls into the research chemical category, sold without a drug claim and without FDA safety review. And on top of all of that, import and state-level rules add a layer of variation this article can only flag, not fully resolve.
None of this changes based on which tools you use to track a protocol. BioStackIQ's Rate My Stack and Peptide Protocol Builder are built to help you organize and evaluate a protocol you've already decided to pursue, they aren't a substitute for understanding the legal category a given substance sits in, or for your own legal and medical judgment about it.
Related Reading
For a closer look at how FDA-approved drugs differ from research peptides in general, see FDA-Approved Peptides vs. Research Peptides. To understand exactly what a "research use only" label does and doesn't mean, see What Does "Research Use Only" Mean?. For how the Section 503A compounding pathway actually works, see What Is a Compounded Peptide?. For the full story behind the FDA's July 2026 committee vote, see What Changed With BPC-157, TB-500 and MOTS-c in 2026, and for the live, per-compound regulatory picture, see the FDA Peptide Status Tracker. For the two FDA-approved GLP-1 drugs specifically, see Semaglutide vs. Tirzepatide. For the safety side of the question, see Are Peptides Safe?, and for the practical steps, see How to Get Peptides Legally.
Frequently Asked Questions
Is BPC-157 legal to buy right now?
It depends on what you mean by legal. BPC-157 is not an FDA-approved drug and is not yet on the FDA's Section 503A Bulk Drug Substances List. Since October 28, 2026, however, a draft HHS policy lets licensed 503A pharmacies compound it for individual patients with a valid prescription, under strict sourcing, testing and labeling conditions. Most BPC-157 sold online is labeled for research use only and not for human consumption, which generally means the seller isn't making a drug claim and the product hasn't gone through FDA safety or efficacy review. This article is general information, not legal advice, so for a definitive answer about your specific situation, talk with a qualified attorney.
What's the difference between FDA-approved and research-use-only peptides?
An FDA-approved peptide drug, like semaglutide or tirzepatide, went through the FDA's full clinical trial process for safety and effectiveness and is available by prescription. A research-use-only peptide, like BPC-157 or TB-500 as they're commonly sold today, has not gone through that review process. The research use only or not for human consumption label is generally how a seller avoids making a drug claim about the product, and it reflects a different regulatory status than FDA approval, not a lesser degree of the same thing.
Does the 2026 FDA vote mean these peptides are legal now?
Not on its own. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six of seven reviewed peptides, including BPC-157, TB-500, and MOTS-c, for the Section 503A Bulk Drug Substances List, and that vote was nonbinding. What changed things was a draft HHS policy announced October 28, 2026, which lets licensed 503A pharmacies compound those six peptides by prescription under strict conditions while FDA completes rulemaking. None of them are on the 503A list yet, and research use only products are still not legal for human use.
Can I get in trouble for buying research peptides?
We can't give you a definitive answer to that, because it depends on facts specific to your situation, including how a product is marketed, how it's used, and where you live, and those are genuinely separate legal questions from whether a research use only label is itself lawful. This article is general information only, not legal advice. If this matters for your specific circumstances, it's worth getting your own legal counsel.
Is it legal for a doctor to prescribe a compounded peptide?
A licensed pharmacy can only legally compound a substance for an individual patient's prescription under Section 503A if that substance is on the FDA's 503A Bulk Drug Substances List, has its own USP or NF monograph, or is a component of an already-approved drug. None of the commonly discussed research peptides meet that standard yet. However, under a draft HHS policy announced October 28, 2026, a licensed 503A pharmacy may compound BPC-157, TB-500, MOTS-c, KPV, Semax or Epitalon for a patient with a valid prescription, under strict conditions. CJC-1295, Ipamorelin, Selank and DSIP are not covered.